

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

NCT06736990

Status	RECRUITING
Phase	Phase 2
Sponsor	Calluna Pharma AS
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (7)

- e 40 years of age
- Diagnosis of IPF supported by centrally read chest high-resolution computed tomography
- Definite or probable usual interstitial pneumonia (UIP) pattern on chest high-resolution computed tomography (HRCT) performed within 12 months of screening, confirmed by central review (if an evaluable HRCT < 12 months is not available, the baseline HRCT will be used to determine eligibility).
- FVC e 45% of predicted (at Screening).
- Diffusing capacity of the lung for carbon monoxide (DLCO) e 25% predicted.
- ... and 2 more (see full listing online)

Exclusion (5)

- In the opinion of the Investigator, other clinically significant lung disease (e.g. asthma, emphysema, chronic obstructive pulmonary disease, cavitory or pleural diseases, clinically significant or treatment-requiring pulmonary hypertension) at screening.
- Interstitial lung disease (ILD) other than IPF (including, but not limited to, connective tissue diseases, vasculitis).
- Acute IPF exacerbation within 16 weeks prior to screening and/or during the screening period (investigator-determined).
- Lower respiratory tract infection requiring antibiotics within 4 weeks prior to screening and/or during the screening period.
- Evidence of impaired kidney function, unstable cardiovascular disease, moderate or severe hepatic impairment or any significant disease or condition other than IPF which may interfere with trial procedures or interpretation of trial results, or cause concern regarding the patient's ability to participate in the trial or any medical condition which could lead to a life expectancy < 12 months

Locations (54 total)

Keck School of Medicine at USC, Los Angeles, California, United States
National Jewish Health, Denver, Colorado, United States
Y & L Advance Health Care, Inc. d/b/a Elite Clinical Research, Miami, Florida, United States
... and 51 more locations

<https://clinicaltrials.gov/study/NCT06736990>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).